Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Blood (2024) 144 (Supplement 1): 230.

https://doi.org/10.1182/blood-2024-209616

Published: 2024

Journal Articles

A Murine Phase 2 Proof-of-Concept Study of Polatuzumab Vedotin in Combination with Venetoclax in Experimental Therapy of BCL2-Positive Aggressive Lymphomas

Dmitry Kazantsev, Eva Pokorna, Kristýna Nožičková, Alexandra Dolníková, Nicol Renešová, Liliana Tuskova, Marek Trněný, Pavel Klener

Blood (2024) 144 (Supplement 1): 974.

https://doi.org/10.1182/blood-2024-194588

Published: 2024

Journal Articles

Circulating Tumor DNA As a Predictor of Survival of DLBCL Patients in a Daily Practice

Iva Hamova, Prokop Vodicka, Adriana Velasova, Kristyna Kupcova, Petra Zemankova, Petr Nehasil, Anton Tkachenko, Kamila Polgarova, Jana Salkova, Katerina Benesova, Pavel Klener, Marek Trneny, Ondrej Havranek

Blood (2024) 144 (Supplement 1): 6235.

https://doi.org/10.1182/blood-2024-211263

Published: 2024

Journal Articles

BMI and Its Changes As a Predictor of Survival in DLBCL Patients

Michal Masar, Prokop Vodicka, Magdalena Klanova, Kamila Polgarova, Katerina Benesova, Diana Malarikova, Jana Salkova, Jan Koren, Pavel Klener, Marek Trneny

Blood (2024) 144 (Supplement 1): 1713.

https://doi.org/10.1182/blood-2024-208542

Published: 2024

Journal Articles

Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?

Liliana Tuskova, Diana Maláriková, Katerina Benesova, Eva Konirova, Kamila Polgarova, Petra Blahovcova, Jana Salkova, Marek Trněný, Pavel Klener

Blood (2024) 144 (Supplement 1): 3012.

https://doi.org/10.1182/blood-2024-198865

Published: 2024

Journal Articles

Comprehensive Genomic Analysis of Non-Relapsed and Late-Relapsed Mantle Cell Lymphoma Patients Compared to Refractory and Early-Relapsed Patients Treated By Standard Immunochemotherapy

Jana Karolova, Dmitry Kazantsev, Lucie Winkowska, Kristina Forsterova, Liliana Tuskova, Diana Malarikova, Veronika Valkova, Andrea Janikova, Ales Obr, Marek Trneny, Pavel Klener

Blood (2024) 144 (Supplement 1): 2973.

https://doi.org/10.1182/blood-2024-198876

Published: 2024

Journal Articles

biomarker Driven Strategies for Targeted Elimination of Hypoxia Adapted Lymphoma Cells

Pavel Klener, Jr., Lenka Daumová, Dmitry Kazantsev, Ladislav Anděra, Jiří Petrák, Alexandra Dolníková, Nardjas Bettazová, Petra Kovaříková, Nicol Renešová, Liliana Tušková, Dana Sovilj, Marek Trněný, Magdalena Klanova, Ondrej Havránek

Blood (2023) 142 (Supplement 1): 4374.

https://doi.org/10.1182/blood-2023-182705

Published: 2023

Journal Articles

Single Cell RNA Sequencing Enables Identification of Mantle Cell Lymphoma Subclones with Drug-Resistant Profiles Already at Diagnosis and May be Used for Therapy Prognostication and Personalization

Dmitry Kazantsev, Magdalena Klanova, Michal Kolář, Robert Ivánek, Marek Trněný, Pavel Klener, Jr.

Blood (2023) 142 (Supplement 1): 3004.

https://doi.org/10.1182/blood-2023-185925

Published: 2023

Journal Articles

DLBCL Patients' Journey: From Symptoms to Diagnosis

Prokop Vodicka, Michal Masar, Magdalena Klanova, Katerina Benesova, Jan Koren, Pavel Klener, Petra Blahovcova, Sarka Hrabetova, Jitka Dlouha, Marek Trněný

Blood (2023) 142 (Supplement 1): 3140.

https://doi.org/10.1182/blood-2023-186207

Published: 2023

Journal Articles

Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients

Prokop Vodicka, Michal Masar, Magdalena Klanova, Katerina Benesova, Jan Koren, Pavel Klener, Petra Blahovcova, Jitka Dlouha, Sarka Hrabetova, Marek Trněný

Blood (2023) 142 (Supplement 1): 4510.

https://doi.org/10.1182/blood-2023-186467

Published: 2023

Journal Articles

BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis

Blood (2023) 142 (13): 1143–1155.

https://doi.org/10.1182/blood.2022019274

Published: 2023

Includes: Supplemental data

Journal Articles

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Heidi Mocikova, Jan Pirnos, Vit Prochazka, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Petra Blahovcova, Vit Campr, Pavel Klener, Jr., Alice Sykorova, Marek Trneny

Blood (2022) 140 (Supplement 1): 3775–3776.

https://doi.org/10.1182/blood-2022-159408

Published: 2022

Journal Articles

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma

Diana Malarikova, Radek Jorda, Alexandra Dolníková, Ondrej Havranek, Eva Pokorna, Dmitry Kazantsev, Dana Sovilj, Karel Helman, Magdalena Klanova, Ladislav Andera, Miroslav Strnad, David Chiron, Marek Trneny, Pavel Klener, Jr.

Blood (2022) 140 (Supplement 1): 5996–5997.

https://doi.org/10.1182/blood-2022-168617

Published: 2022

Journal Articles

BCL-XL Blockage with A1155463 Significantly Increases Efficacy of Venetoclax in Mantle Cell Lymphoma in Vitro and In Vivo

Alexandra Dolníková, Dmitry Kazantsev, Diana Malarikova, Eva Pokorna, Dana Sovilj, Cristina Daniela Kelemen, Ladislav Andera, Marek Trněný, Pavel Klener, Jr.

Blood (2022) 140 (Supplement 1): 6383–6384.

https://doi.org/10.1182/blood-2022-170109

Published: 2022

Journal Articles

Inhibition of MAPK-ERK Signaling Pathway Overcomes Microrna-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma

Olga Kersy, Mali Salmon-Divon, Maria Gomes da Silva, Ana Filipa Moita, Jose Cabecadas, Pavel Klener, Jr., Marek Trněný, May Basood, Ofer Shpilberg, Oshrat Hershkovitz-Rokah

Blood (2022) 140 (Supplement 1): 3109–3110.

https://doi.org/10.1182/blood-2022-169574

Published: 2022

Journal Articles

Sequencing-Based Analysis of Clonal Evolution of 25 Mantle Cell Lymphoma Patients at Diagnosis and after Failure of Standard Immunochemotherapy

Jana Karolova, Dmitry Kazantsev, Michael Svaton, Liliana Tušková, Kristina Forsterova, Diana Malarikova, Katerina Benesova, Tomáš Heizer, Alexandra Dolníková, Magdalena Klanova, Eva Fronkova, Marek Trněný, Pavel Klener, Jr.

Blood (2022) 140 (Supplement 1): 6409–6410.

https://doi.org/10.1182/blood-2022-166069

Published: 2022

Journal Articles

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Blood (2022) 140 (17): 1907–1916.

https://doi.org/10.1182/blood.2022015560

Published: 2022

Includes: Supplemental data

Journal Articles

Combination Benefit of Capivasertib and Venetoclax in Preclinical Models of Diffuse Large B-Cell Lymphoma

Brandon Willis, India Neveras, Hannah Dry, Wendan Xu, Yang Li, Kevin Mongeon, Justine Roderick, Alan Rosen, Pavel Klener, Jr., Georg Lenz, Jerome Mettetal, Simon Barry

Blood (2021) 138 (Supplement 1): 1870.

https://doi.org/10.1182/blood-2021-153711

Published: 2021

Journal Articles

Ibrutinib in Mantle Cell Lymphoma Patients: Analysis of the Czech Lymphoma Study Group

Aleš Obr, Pavel Klener, Jr., Andrea Janíková, Heidi Mocikova, David Belada, David Šálek, Alice Sýkorová, Andrea Jirkuvová, Tomáš Papajík, Marek Trněný

Blood (2021) 138 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2021-146589

Published: 2021

Journal Articles

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BCL2 Inhibitor Venetoclax in Experimental Models of Chemotherapy Refractory Mantle Cell Lymphoma

Diana Malarikova, Radek Jorda, Alexandra Dolnikova, Eva Pokorna, Dmitry Kazantsev, Ondrej Havranek, Karel Helman, Magdalena Klanova, Miroslav Strnad, Marek Trneny, Pavel Klener, Jr.

Blood (2021) 138 (Supplement 1): 1203.

https://doi.org/10.1182/blood-2021-150517

Published: 2021

NARROW

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

A Murine Phase 2 Proof-of-Concept Study of Polatuzumab Vedotin in Combination with Venetoclax in Experimental Therapy of BCL2-Positive Aggressive Lymphomas

Circulating Tumor DNA As a Predictor of Survival of DLBCL Patients in a Daily Practice

BMI and Its Changes As a Predictor of Survival in DLBCL Patients

Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?

Comprehensive Genomic Analysis of Non-Relapsed and Late-Relapsed Mantle Cell Lymphoma Patients Compared to Refractory and Early-Relapsed Patients Treated By Standard Immunochemotherapy

biomarker Driven Strategies for Targeted Elimination of Hypoxia Adapted Lymphoma Cells

Single Cell RNA Sequencing Enables Identification of Mantle Cell Lymphoma Subclones with Drug-Resistant Profiles Already at Diagnosis and May be Used for Therapy Prognostication and Personalization

DLBCL Patients' Journey: From Symptoms to Diagnosis

Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients

BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma

BCL-XL Blockage with A1155463 Significantly Increases Efficacy of Venetoclax in Mantle Cell Lymphoma in Vitro and In Vivo

Inhibition of MAPK-ERK Signaling Pathway Overcomes Microrna-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma

Sequencing-Based Analysis of Clonal Evolution of 25 Mantle Cell Lymphoma Patients at Diagnosis and after Failure of Standard Immunochemotherapy

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Combination Benefit of Capivasertib and Venetoclax in Preclinical Models of Diffuse Large B-Cell Lymphoma

Ibrutinib in Mantle Cell Lymphoma Patients: Analysis of the Czech Lymphoma Study Group

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BCL2 Inhibitor Venetoclax in Experimental Models of Chemotherapy Refractory Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only